Selenium or no selenium-that is the question in tumor patients: A new controversy

Integrative Cancer Therapies

Volumn 9, Issue 2, 2010, Pages 136-141

  Muecke, Ralph ^a   Schomburg, Lutz ^b   Buentzel, Jens ^c   Kisters, Klaus ^d   Micke, Oliver ^e  

^a LIPPE HOSPITAL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Suedharz Hospital   (Germany)

^d ST ANNA HOSPITAL   (Germany)

^e FRANZISKUS HOSPITAL   (Germany)

Author keywords

cytoprotection; primary and secondary cancer prevention; radioprotection; selenium; tumor patients

Indexed keywords

ALPHA TOCOPHEROL; FINASTERIDE; PLACEBO; SELENIUM; SELENOCYSTEINE; SELENOMETHIONINE; SELENOPROTEIN; SODIUM SELENITE; TRACE ELEMENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

ANTIOXIDANT ACTIVITY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CELL DEATH; CELL PROTECTION; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG EFFECT; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME STRUCTURE; GYNECOLOGIC CANCER; GYNECOMASTIA; HUMAN; IMPOTENCE; INFECTION RISK; LYMPHOMA CELL; MALE TYPE ALOPECIA; METASTASIS; MOOD CHANGE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RADIATION PROTECTION; REDOX STRESS; REVIEW; SECOND CANCER; SELENIUM DEFICIENCY; TUMOR CELL; VITAMIN SUPPLEMENTATION; ANIMAL; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); NEOPLASMS;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; NEOPLASMS; SELENIUM; TRACE ELEMENTS;

EID: 77954198183     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410367648     Document Type: Review

References (46)

1. Papp LV, Lu J., Holmgren A., Khanna KK From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007; 9: 775-806.
2. Schomburg L., Koehrle J. Selenium: benefits and risks. MMW Fortschr Med. 2007; 149: 34-36.
3. Rayman MP The importance of selenium to human health. Lancet. 2000; 356: 233-241.
4. Johnson CC, Fordyce FM, Rayman MP Symposium on "Geographical and geological influences on nutrition": Factors controlling the distribution of selenium in the environment and their impact on health and nutrition. Proc Nutr Soc. 2010; 69: 119-132.
5. Schomburg L., Koehrle J. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol Nutr Food Res. 2008; 52: 1235-1246.
6. Méplan C., Nicol F., Burtle BT, et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal. 2009; 11: 2631-2640.
7. Ashton K., Hooper L., Harvey LJ, Hurst R., Casgrain A., Fairweather-Tait SJ Methods of assessment of selenium status in humans: a systematic review. Am J Clin Nutr. 2009; 89: 2025S-2039S.
8. Xia Y., Hill KE, Byrne DW, Xu J., Burk RF Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr. 2005; 81: 829-834.
9. Schomburg L., Schweizer U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim Biophys Acta. 2009; 1790: 1453-1462.
10. Burk RF, Hill KE, Motley AK Plasma selenium in specific and non-specific forms. Biofactors. 2001; 14: 107-114.
11. Combs GF Jr. Selenium in global food systems. Br J Nutr. 2001; 85: 517-547.
12. Brooks JD, Metter EJ, Chan DW Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001; 166: 2034-2038.
13. Kellen E., Zeegers M., Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol. 2006; 13: 1180-1184.
14. Knekt P., Aromaa A., Mantela J. Serum selenium and subsequent risk of cancer among Finnish men and woman. J Natl Cancer Inst. 1990; 82: 864-868.
15. Muecke R., Buentzel J., Glatzel M., et al. Postoperative serum and whole blood selenium levels in patients with squamous cell and adenocarcinomas of the uterus after curative surgical treatment. Trace Elem Electrolytes. 2009; 26: 78-82.
16. Pawlowicz Z., Zachara BA, Trafikowska U., Maciag A., Marchaluk E., Nowicki A. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis. 1991; 5: 272-277.
17. Torun M., Aldemir H., Yardim S. Serum selenium levels in various cancer types. Trace Elem Electrolytes. 1995; 12: 186-190.
18. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996; 276: 1957-1963.
19. Yu SY, Zhu YJ, Li WG et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res. 1991; 29: 289-294.
20. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003; 91: 608-612.
21. Gudkov AV Converting p53 from a killer to a healer. Nat Med. 2002; 8: 1196-1198.
22. Fischer JL, Mihelc EM, Pollok KE, Smith ML Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther. 2007; 6: 355-361.
23. Vunta H., Davis F., Palempalli UD, et al. The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta-12, 14-prostaglandin J2 in macrophages. J Biol Chem. 2007; 282: 17964-17973.
24. Beck MA, Nelson HK, Shi Q., et al. Selenium deficiency increases the pathology of an influenza virus infection. FASEB J. 2001; 15: 1481-1483.
25. Buentzel J., Muecke R., Micke O. Mineral status and enzymatic antioxidative capacities during radiochemotherapy in patients with advanced head and neck cancer. Trace Elem Electrolytes. 2000; 18: 98.
26. Buentzel J., Micke O., Muecke R., et al. Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer-redox status data. Trace Elem Electrolytes. 2005; 22: 211-215.
27. Micke O., Buentzel J., Bruns F., et al. Clinical elementology in oncology: experiences and proposals from Germany. Trace Elements Electrolytes. 2008; 25: 221.
28. Schueller P., Puettmann S., Muecke R., et al. From the radiolysis of water to the role of trace elements in radiobiology and clinical radiation therapy: following a logical chain. Trace Elem Electrolytes. 2001; 18: 186-192.
29. Doerr W. Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther Onkol. 2006; 182: 693-695.
30. Funke AM Potential of selenium in gynecological oncology. Med Klin. 1999; 94: 42-44.
31. Fraunholz I., Jueling-Pohlit L., Boettcher H. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors. Trace Elem Electrolytes. 2001; 18: 98-99.
32. Gehrisch A., Doerr W. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol. 2007; 183: 36-42.
33. Hehr T., Hoffmann W., Bamberg M. Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma. Med Klin. 1997; 92 (Suppl 3). 48-49.
34. Patchen ML, MacVittie TJ, Weiss JF Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys. 1990; 18: 1069-1075.
35. Vermeulen N., Baldew GS, Los G., McVie JG, De Goeij JM Reduction of cisplatinum nephrotoxicity by sodium selenite. Drug Metabol Dispos. 1993; 21: 30-36.
36. Weijl NI, Elsendoorn TJ, Lentjes EG, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004; 40: 1713-1723.
37. Last KW, Cornelius V., Delves T., et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21: 2335-2341.
38. Last K., Maharaj L., Perry J., et al. The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol. 2006; 17: 773-779.
39. Muecke R., Schomburg L., Glatzel M., et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology [published ahead of print February 2, 2010]. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2009.08.013
40. Bleys J., Navas-Acien A., Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008; 168: 404-410.
41. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009; 301: 39-51.
42. Moyad MA Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002; 59 (4 Suppl 1). 9-19.
43. Wilt TJ, MacDonald R., Hagerty K., Schellhammer P., Kramer BS Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008; 2: CD007091.
44. Stranges S., Marshall JR, Natarajan R., et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 147: 217-223.
45. Chan JM, Oh WK, Xie W., et al. Plasma selenium, manganese superoxide dismutase, and intermediate-or high-risk prostate cancer. J Clin Oncol. 2009; 27: 3577-3583.
46. Dennert G., Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. 2006; 3: CD005037.